Circulating miR-148b and miR-133a as biomarkers for breast cancer detection
Jie Shen(The University of Texas MD Anderson Cancer Center), Song Liu(University of Science and Technology of China), Peter A. Fasching(Universitätsklinikum Erlangen), Michael Schrauder(Friedrich-Alexander-Universität Erlangen-Nürnberg), Song Yao(Roswell Park Comprehensive Cancer Center), Hua Zhao(University of Virginia), Christine B. Ambrosone(Unknown), Matthias W. Beckmann(Universitätsklinikum Erlangen), Maochun Qin(Roswell Park Comprehensive Cancer Center), Reiner Strick(Friedrich-Alexander-Universität Erlangen-Nürnberg), Qianqian Zhu(Roswell Park Comprehensive Cancer Center), Candace S. Johnson(Roswell Park Comprehensive Cancer Center), Yuqing Guo(Roswell Park Comprehensive Cancer Center), Dan Wang(Tianjin University of Traditional Chinese Medicine), Li Yan(Sanford Burnham Prebys Medical Discovery Institute), Biao Liu(Hong Kong Baptist University), Qiang Hu(Wuhu Fourth People Hospital), Leonardo Medico(Roswell Park Comprehensive Cancer Center)
Cited by 85
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k